The invention concerns a loaded extracellular vesicle (EV) such as an exosome, wherein the EV has been loaded with a cargo molecule covalently or non-covalently coupled to a cell penetrating polypeptide (resulting in a “binding complex”), and the cargo molecule or binding complex has been internalized by, or is associated with, the EV. Another aspect of the invention concerns a method for loading an EV with a cargo molecule, comprising contacting the EV with the binding complex, wherein the binding complex becomes internalized by, or associated with, the EV. Another aspect of the invention concerns a method for delivering a cargo molecule into a cell in vitro or in vivo, comprising administering a loaded EV to the cell in vitro or in vivo, wherein the loaded EV is internalized into the cell, and wherein the loaded EV comprises the cargo molecule covalently or non-covalently bound to a cell penetrating polypeptide.

Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest.

The present disclosure relates to methods of releasing a target molecule from intein complexes comprising an intein-C tagged target molecule and intein-N polypeptides, by contacting the intein complexes with nitrogen containing heteroaromatic derivatives, and/or by increasing residence time of intein complexes in a medium effective to remove the target molecule. Modulating the pH further facilitates target release.

This disclosure is directed to split intein protein production systems using transgenic target organisms such as Bombyx mori. A vector set for transforming a target organism includes: a first vector having a first donor sequence that encodes (i) a first non-native protein and (ii) at least one split intein domain; a second vector having a second donor sequence that encodes (i) a second non-native protein and (ii) at least one split intein domain. The respective split intein domains encoded by the first and second vectors are configured to associate with one another and ligate the first and second non-native proteins to thereby form a fused protein.

Provided herein are CD79b antibodies and CD79b-specific chimeric antigen receptors (CARs). Further provided herein are T cells expressing the CD79b-specific CARs and methods of treating cancer by administering the CD79b-specific CAR T cells.

Disclosed herein are chimeric receptors and precursors, chimeric antigen receptors and precursors, universal chimeric receptor cell precursors, chimeric antigen receptor T cells, and methods of constructing and using the same.

Embodiments of the present invention relate to inteins, split inteins, compositions comprising inteins and methods for use of these.

The present disclosure describes a Mtu ΔI-CM intein variant containing one or more mutations or a biologically active fragment thereof, and a method for producing and purifying a molecule of interest using the intein variant. Further described are isolated fusion proteins comprising the intein variant and a tag and a molecule of interest. Also described are expression systems for expressing the intein variant as well as polypeptide screening methods employing the intein variant.

Methods and compositions are provided for editing the genome of a cell without the use of an exogenously supplied nuclease. Aspects of the methods include contacting a cell with a targeting vector comprising nucleic acid sequence to be integrated into the target locus, where the cell is not also contacted with a nuclease. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided.

The present invention relates to the field of chromatography and more specifically to producing protein affinity chromatography resins comprising affinity ligands based on a N-terminal fragment of a split intein, such as DnaE from Nostoc punctiforme, as well as methods for using the same. The N-terminal fragments are produced in inclusion bodies in bacterial cells.